Humacyte, Inc. (HUMA) stock
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.56−0.04 (-6.21%)
Close on Nov 13, 2026Market cap $155.12MP/E –Yield –
Humacyte revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Humacyte's revenue for the twelve months ending Sep 30, 2026 was $2.40M, up 52.5% year over year. For fiscal 2025 it was $2.04M.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.03M | +36.5% |
| Q2 FY2026 | Jun 30, 2026 | $406.00K | +34.9% |
| Q1 FY2026 | Mar 31, 2026 | $495.00K | -4.3% |
| Q4 FY2025 | Dec 31, 2025 | $467.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $753.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $301.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $517.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $241.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $914.00K | – |
See a number that looks wrong?